Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-10-13

Last Posted Date: 2017-11-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 59

Registration Number: NCT00238368

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Phase 2

Completed

Conditions: Essential Thrombocythemia
Primary Myelofibrosis
Polycythemia Vera

Interventions: Drug: lenalidomide
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2005-09-28

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00227591

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Phase 2

Terminated

Conditions: Hodgkin Disease

Interventions: Drug: Doxorubicin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Vincristine
Drug: Bleomycin
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Prednisone

First Posted Date: 2005-09-23

Last Posted Date: 2014-08-27

Lead Sponsor: Stanford University

Target Recruit Count: 45

Registration Number: NCT00225173

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: bevacizumab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: prednisone
Drug: vincristine

First Posted Date: 2005-09-22

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 46

Registration Number: NCT00217425

Locations: 🇺🇸
Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸
Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸
California Cancer Care, Incorporated - Greenbrae, Greenbrae, California, United States

and more 107 locations

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Phase 3

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: BCNU
Drug: Cisplatinum
Drug: Melphalan
Drug: Ara-C
Drug: Etoposide
Drug: Dexamethasone
Drug: G-CSF
Procedure: stem cell harvest
Procedure: total body irradiation

First Posted Date: 2005-09-21

Last Posted Date: 2012-09-10

Lead Sponsor: European Mantle Cell Lymphoma Network

Target Recruit Count: 360

Registration Number: NCT00209222

Locations: 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪
German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱
The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: Denileukin diftitox
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Other: Pegfilgrastim

First Posted Date: 2005-09-21

Last Posted Date: 2020-03-18

Lead Sponsor: Eisai Inc.

Target Recruit Count: 49

Registration Number: NCT00211185

Locations: 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 44 locations

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Phase 3

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Fludarabine
Procedure: Rituximab maintenance
Drug: Vincristine
Drug: Prednisone
Drug: Interferon-alpha
Drug: pegylated formula Interferon-alpha 2b
Procedure: Interferon maintenance

First Posted Date: 2005-09-21

Last Posted Date: 2017-03-07

Lead Sponsor: European Mantle Cell Lymphoma Network

Target Recruit Count: 570

Registration Number: NCT00209209

Locations: 🇳🇱
HOVON - Dutch Haemato-Oncology Association (HOVON-Datacenter), Rotterdam, Netherlands
🇩🇰
Nordic Lymphoma Group, Copenhagen, Denmark
🇩🇪
German Low Grade Study Group (Glsg), Munich, Germany

and more 4 locations